XYWAV (Calcium Oxybate; Magnesium Oxybate; Potassium Oxybate; Sodium Oxybate) Patent Expiration, LOE Window & CMS Spending

XYWAV (Calcium Oxybate; Magnesium Oxybate; Potassium Oxybate; Sodium Oxybate) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2033-01-11 (last listed 2041-02-22), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN212690 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-01-11
Last Listed Patent or Exclusivity Date2041-02-22
Orange Book Patents (*PED Extensions)25 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.